Eugene Protzko is an Ophthalmology physician affiliated with Grace. OpenAlex indexes 21 publications with 634 citations (h-index 11); ClinicalTrials.gov lists 3 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
2023 Pulaski Highway
Havre De Grace, MD 21078
Telephone
410-939-6477Provider last certified this registry record 2 Jun 2023.
Clinical trials
- A Multi-Center, Vehicle-Controlled, Parallel-Group Study Evaluating the Safety of AC-170 Ophthalmic Solution
Sponsor: Nicox Ophthalmics, Inc.
- A Multi-Center Study Evaluating the Safety of AC-170 0.24%
Sponsor: Aciex Therapeutics, Inc.
- A Single-Center,Evaluation of the Onset and Duration of Action of AC-170 0.24% Compared to Vehicle
Sponsor: Aciex Therapeutics, Inc.
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
22 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Tarsus Pharmaceuticals, Inc.Program year20254 payments
- ABBVIE INC.Program year20252 payments
- Bausch & Lomb Americas Inc.Program year20252 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Sensory organs
65.5%Prostaglandin Analog32%Latanoprost86%Lumigan9%Travoprost5%Part D<11 patientsCorticosteroid12.4%Prednisolone Acetate92%Fluorometholone8%Part D<11 patients+ 6 more classes in this area
Cardiovascular
12.1%Beta blocker12.1%Timolol Maleate100%Part D≥58 patientsCancer & immunology
9.9%Calcineurin inhibitor9.9%Cyclosporine50%Restasis50%Part D≥32 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- A Review of the First Anti-Evaporative Prescription Treatment for Dry Eye Disease: Perfluorohexyloctane Ophthalmic Solution
The American Journal of Managed Care
2023 - Once-Daily Netarsudil Versus Twice-Daily Timolol in Patients With Elevated Intraocular Pressure: The Randomized Phase 3 ROCKET-4 Study
American Journal of Ophthalmology
2019 - Results of A Randomized, Double-Masked, Parallel-Arm Phase 2b Study Evaluating the Safety and Efficacy of OTX-TP (travoprost insert) Compared to Timolol Drops for the Treatment of Patients with Open-Angle Glaucoma or Ocular Hypertension2017
- DEXTENZATM (extended release dexamethasone) 0.4 mg vs. Placebo for the Treatment of Ocular Pain after Cataract Surgery: Results of Three Phase 3 Studies2017
Similar KOLs
Other experts from the same institution or the same specialty.
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”